We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.
- Porphyrin precursors